NKGNW
NKGen Biotech, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0012
- Prev close
- 0.0012
- Mkt cap
- 6.18M
- Vol
- 100
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0012
- High
- 0.0012
- Forward P/E
- 0.00
- Beta
- 0.52
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 12.75M
- Total cash
- 79.00K
- Total debt
- 28.09M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About NKGen Biotech, Inc.
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkgenbiotech.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on NKGNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 0.00% | 87,717 | 6.14K | Sep 29, 2024 |
| Healthcare of Ontario Pension Plan Trust Fund | 0.00% | 100,000 | 7.00K | Sep 29, 2024 |
| Exos Asset Management LLC | 0.00% | 88,354 | 6.18K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 0.00% | 159,266 | 11.15K | Sep 29, 2024 |
| BNP Paribas Financial Markets | 0.00% | 150,000 | 10.50K | Sep 29, 2024 |
| Shaolin Capital Management LLC | 0.00% | 128,274 | 8.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RiverNorth Opportunities Fd | 0.00% | 9,664 | 676 | Sep 29, 2024 |
| RiverNorth Capital & Income Fund, Inc. | 0.00% | 4,459 | 312 | Sep 29, 2024 |
| First Tr Exchange Traded Fd-First Trust Alternative Opportunities Fd | 0.00% | 577 | 40 | Sep 29, 2024 |